• Vaccine Name: CAdVax-ZEBOV/SEBOV
• Target Pathogen: Ebola virus
• Target Disease: Ebola hemorrhagic fever
• Vaccine Ontology ID: VO_0004641
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001086
• Preparation: A multivalent vaccine candidate (EBO7) that expresses the glycoproteins of Zaire ebolavirus (ZEBOV) and Sudan ebolavirus (SEBOV) in a single complex adenovirus-based vector (CAdVax) (Pratt et al., 2010).
• Immunization Route: Intramuscular injection (i.m.)

Macaque Response

• Vaccination Protocol: For the parenteral challenge studies, cynomolgus macaques were vaccinated intramuscularly (i.m.) on day zero with a 1:1 mixture of 1 × 10^10 PFU each of EBO7 and M8 (total 2 × 10^10 PFU). Control animals received an i.m. injection of 2 × 10^10 PFU of HC4. For the initial aerosol infection experiments, cynomolgus macaques were vaccinated by i.m. injection of 1 × 10^10 PFU of EBO7 or 1 × 10^10 PFU of HC4 (Pratt et al., 2010).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: For the aerosol infection group, twenty-eight days after vaccination, animals were anesthetized and exposed to a target dose of 1,000 PFU of either aerosolized ZEBOV or aerosolized SEBOV. For the parenteral challenge studies, six weeks after the boosting vaccinations, the macaques were anesthetized by i.m. injection of Telazol (2 to 6 mg/kg of body weight) and then inoculated i.m. with SEBOV or ZEBOV challenge stock (Pratt et al., 2010).
• Efficacy: EBO7 vaccine provided protection against both Ebola viruses by either route of infection. Significantly, protection against SEBOV given as an aerosol challenge, which has not previously been shown, could be achieved with a boosting vaccination (Pratt et al., 2010).